Short-Course Radiotherapy Supports Organ Preservation in Locally Advanced Rectal Cancer / locally advanced rectal cancer, ...
A new PET imaging approach detected 97.9% of lesions in clear cell renal cell carcinoma (ccRCC), potentially giving ...
ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved as a self-administered once-daily, subcutaneous ...
Six ESMO Trials that Changed Cancer Treatment / cancer, Destiny-Breast03, Durvalumab, enfortumab vedotin pembrolizumab, ESMO, ...
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) as ...
Patient’s Skin Improved from Severe to Clear with Complete Elimination of Pruritus (itch) – After 21 Months of Treatment with ...
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple ...
In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary ...
If approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second lineCHMP recommendation ...
On October 15, 2026, the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council's ...
MoonLake Immunotherapeutics BLA filing for sonelokimab in HS, VELA phase 3 HiSCR75 data, and PsA IZAR-1 readouts—click to see ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results